ContraFect

ContraFect EV/Revenue

EV/Revenue (Enterprise Value to Revenue) of ContraFect (CFRXQ) as of Oct 19, 2026.

EV/Revenue

-

Last updated:

EV/Revenue (Enterprise Value to Revenue) of ContraFect is 2026 - . EV/Revenue (Enterprise Value to Revenue) of ContraFect was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) ContraFect since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s ContraFect with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ContraFect

All Key Metrics — ContraFect